Anti-CD138 chimeric antigen receptor-modified T cell therapy for multiple myeloma with extensive extramedullary involvement

被引：25
|
作者：
Tian, Chen [1 ]
Yang, Hongliang [1 ]
Zhu, Lei [1 ]
Zhang, Qing [1 ]
Cao, Zeng [1 ]
Zhang, Yizhuo [1 ]
机构：
[1] Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China
来源：
ANNALS OF HEMATOLOGY | 2017年 / 96卷 / 08期
基金：
中国国家自然科学基金;
关键词：
D O I：
10.1007/s00277-017-3029-3
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1407 / 1410
页数：4
相关论文
共 50 条
  • [31] Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy
    O'Hara, Mark
    Stashwick, Caitlin
    Haas, Andrew R.
    Tanyi, Janos L.
    IMMUNOTHERAPY, 2016, 8 (04) : 449 - 460
  • [32] Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells
    Jensen, Michael C.
    Riddell, Stanley R.
    IMMUNOLOGICAL REVIEWS, 2014, 257 (01) : 127 - 144
  • [33] Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy
    Hu, Yongxian
    Sun, Jie
    Wu, Zhao
    Yu, Jian
    Cui, Qu
    Pu, Chengfei
    Liang, Bin
    Luo, Yi
    Shi, Jimin
    Jin, Aiyun
    Xiao, Lei
    Huang, He
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2016, 9
  • [34] Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy
    Yongxian Hu
    Jie Sun
    Zhao Wu
    Jian Yu
    Qu Cui
    Chengfei Pu
    Bin Liang
    Yi Luo
    Jimin Shi
    Aiyun Jin
    Lei Xiao
    He Huang
    Journal of Hematology & Oncology, 9
  • [35] An Immune Based, Anti-CD138 Targeting Antibody for the Treatment of Multiple Myeloma
    Yu, Tengteng
    Xing, Lijie
    Lin, Liang
    Liu, Jiye
    Wen, Kenneth
    Cho, Shih-Feng
    Hsieh, Phillip
    Myette, James
    Chaganty, Bharat
    Adari, Hedy
    Tissire, Hamid
    Deotale, Ketan
    Shriver, Zach
    Munshi, Nikhil
    Tai, Yu-Tzu
    Anderson, Kenneth
    BLOOD, 2018, 132
  • [36] Chimeric antigen receptor-modified T cells: CD19 and the road beyond
    Salter, Alexander I.
    Pont, Margot J.
    Riddell, Stanley R.
    BLOOD, 2018, 131 (24) : 2621 - 2629
  • [37] Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer
    Marcus, Assaf
    Eshhar, Zelig
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2014, 14 (07) : 947 - 954
  • [38] Chimeric antigen receptor T cell therapies for multiple myeloma
    Wu, Chao
    Zhang, Lina
    Brockman, Qierra R.
    Zhan, Fenghuang
    Chen, Lijuan
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2019, 12 (01)
  • [39] Chimeric antigen receptor T cell therapies for multiple myeloma
    Chao Wu
    Lina Zhang
    Qierra R. Brockman
    Fenghuang Zhan
    Lijuan Chen
    Journal of Hematology & Oncology, 12
  • [40] Chimeric Antigen Receptor-Modified T Cells in CLL REPLY
    Kalos, Michael
    Porter, David L.
    June, Carl H.
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (20): : 1938 - 1938
12345